The recent, sudden declines in breast cancer incidence in the United States ( 1 , 2 ) are unprecedented, and their origins are of great relevance to breast cancer prevention. To date, large population-based declines in breast cancer have been reported not only for the United States but also for Germany and New Zealand, although not for Norway, Sweden, and the Netherlands. Because hormone therapy (HT) use declined substantially in all of these areas after 2002 , it has been suggested ( 3 ) that this variation in worldwide incidence trends weakens the conclusions of Kerlikowske et al. ( 2 ) and others that HT cessation was the major cause of the declines. We wish to note some relevant mathematical and biologic considerations.
First, consider a change in the prevalence ( P ), from P 1 to P 2, of a risk factor with relative risk = RR. The percent change in incidence (PCI) that would be expected is PCI RR RR . = + P P P
Suppose that the change in P is − 65%. It should be noted that the same − 65% change could represent a change from 13% to 5% ( P 1 = 0.13, P 2 = 0.05) or from 38% to 13% ( P 1 = 0.38, P 2 = 0.13). Let us also suppose that RR = 1.25. Under these conditions, PCI = − 2% if P 1 = 0.13, but PCI = − 6% if P 1 = 0.38. Clearly, it is not the percent change in P that drives changes in incidence but the absolute change in P . Regarding the impact of changing relative risk, let us assume that P changed from 38% to 13% but that in one scenario RR = 1.25 and in the other RR = 1.07. Here, PCI = − 2% if RR = 1.07, but PCI = − 6% if RR = 1.25. Again, it is clear that PCI is lower when the relative risk is lower.
In addition to duration of use, the relative risk associated with HT use may also depend on the specifi c HT formulation. The 13% rate would be lower and possibly statistically insignifi cant had a later time cutoff ("knot") been chosen. Although no difference in the incidence of ER-negative invasive cancers was found during this same period, ER-negative cancers represented less than 25% of the invasive breast cancers in the study population (<1 ER-negative case per 1000 mammograms). The number of ER-negative cases was therefore too small to show a change in incidence, even with sophisticated statistical modeling techniques.
Mammographically detected ER-positive cancers in postmenopausal women are, on average, clinically favorable cancers that change slowly over time, taking years to develop. The idea that a preexisting ER-positive cancer would rapidly disappear within a year of HRT discontinuation is biologically implausible. Were discontinuation of HRT to affect preexisting hormonesensitive cancers, one would expect a corresponding change in incidence to take years to become demonstrable. Because no lag was observed between decreased HRT use and decreased breast cancer incidence in this study, other mechanisms to explain the fi ndings should be considered.
If HRT causes hormone-sensitive cancers to "light up" and be more easily detected on mammograms, then discontinuation of HRT would reduce breast cancer detection at least for a period of time. This pattern is precisely what the authors observed. Did decreased HRT use simply delay the diagnoses of existing breast cancers in this mammographically screened population? Further follow-up needs to be performed. Until then, we should be cautious and circumspect before making sweeping clinical generalizations based on complex epidemiologic results that may be of negligible importance when considered at the level of the individual patient. Elimination of HRT would barely dent the current breast cancer epidemic but could have substantial adverse effects for women whose quality of life can really benefi t from HRT.
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Response
The magnitude of decline in invasive breast cancer has been remarkably consistent across studies ( 1 -4 ) . Two of the main proposed causes for the decline are a decrease in screening mammography and a decline in use of postmenopausal hormone therapy (HT). We reported a decline in invasive cancer of 5% annually or 15% over a period of 3 years and a decline of estrogen receptor (ER) -positive invasive cancer of 13% annually or 26% over a period of 2 years in a population of women undergoing routine mammography in which the time between screening examinations was similar among current users of HT, former users of HT, and nonusers. The annual decline in ER-positive breast cancer remained comparable and statistically significant ( P trend = .01) to what we reported even when we omit the first two data points in 2001 and last data point in 2003, despite Anderson ' s suggestion that these data points drove our statistically significant findings. In summary, we have shown that a decline in screening mammography rates is unlikely to account for the recent decline in US breast cancer incidence.
Anderson suggests that, because the breast cancer rate we reported was virtually unchanged between 1997 and 2004 and the decline in breast cancer starting in 2000 was not proportional to the decline in HT use, it is hard to conclude that there is any relation between HT use and decline in invasive breast cancer. However, given that mammography use does not account for the decline in breast cancer rate that we observed, our results -particularly the corresponding changes in rates of HT use and breast cancer over time -do suggest that the precipitous decline in HT use likely played a part in the change in breast cancer rates. For example, we observed a statistically signifi cant ( P trend <.001) 2% annual increase in HT use from 1997 to 2000 and a concomitant statistically signifi cant 9% annual increase in invasive cancer from 1998 to 2000 ( P trend = .03). Likewise, as the rate of HT use started to decline in 2000, we observed a statistically signifi cant 5% annual decline in invasive cancer, as noted above. Robbins and Clarke state that a percentage change in breast cancer incidence is dependent on the absolute change in prevalence of HT use and the relative increase in breast cancer risk among HT users compared with nonusers. We observed a 31.6% absolute decrease in HT prevalence from 2000 to 2004, but a lower 15% overall decline in breast cancer rate because invasive breast cancer risk is increased only 24% (95% confi dence interval [CI] = 2% to 50%) in HT users relative to nonusers ( 5 ). We observed a greater decline in the rate of ERpositive breast cancer (26% over a period of 2 years) because ER-positive breast cancer risk is 72% (95% CI = 55% to 90%) higher in HT users than in nonusers ( 6 ) .
Potential mechanisms that could result in a decline in breast cancer incidence are shown in Table 1 . Of these potential mechanisms, we have shown that screening mammography use is not likely to account for a decline in breast cancer rates but that a decline in HT use likely plays a role. Measuring ER-positive breast cancer rates in continuous, former, and never users of postmenopausal HT may inform our understanding of the magnitude of the contribution of declines in postmenopausal HT use on breast cancer incidence.
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